Bacterial infections:

Indications for: DALVANCE

Susceptible acute bacterial skin and skin structure infections (ABSSSI).

Adult Dosage:

Give by IV infusion over 30mins. CrCl ≥30mL/min: administer 1500mg as single dose, or 1000mg followed by 500mg one week later. Renal impairment (CrCl <30mL/min) and who are not receiving regularly scheduled hemodialysis: administer 1125mg as single dose, or 750mg followed by 375mg one week later.

Children Dosage:

CrCl <30mL/min/1.73m2 (<18yrs): not established. Give by IV infusion over 30mins. CrCl ≥30mL/min/1.73m2 (birth–<6yrs): administer 22.5mg/kg as single dose (max 1500mg); (6–<18yrs): administer 18mg/kg as a single dose (max 1500mg).

DALVANCE Warnings/Precautions:

History of glycopeptide allergy. Discontinue if hypersensitivity reactions occur; treat appropriately. Moderate or severe hepatic impairment (Child-Pugh Class B or C). Renal impairment (CrCl <30mL/min). Pregnancy. Nursing mothers.

DALVANCE Classification:


Adverse Reactions:

Nausea, headache, diarrhea, vomiting, rash, pruritus; in children: pyrexia; ALT elevations, infusion-related reactions, hepatic effects, C. difficile-associated diarrhea (discontinue if occurs).


~93% plasma protein binding.

Drug Elimination:

Renal, fecal. Half-life: ~8.5 days (204 hours).

Generic Drug Availability:


How Supplied:

Single-use vial—1